Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

pembrolizumab 299Carboplatin 229Cisplatin 159Gemcitabine 152Paclitaxel 151Pemetrexed 121Bevacizumab 121Docetaxel 106Oxaliplatin 82durvalumab 81Nivolumab 81Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 77130-nm albumin-bound paclitaxel 73Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 56fludarabine 51Lenalidomide 50venetoclax 46Prednisone 45Letrozole 42Irinotecan 42enzalutamide 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Panzyga × 90 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡